Clinical trials
Moderate to Severe Atopic Dermatitis clinical trials
Below are recruiting moderate to severe atopic dermatitis clinical trials, each written for real people, not researchers. We’re tracking 95 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06808477RecruitingPhase 1
BBT001 for moderate to severe eczema
This trial tests an experimental drug called BBT001 for people with moderate to severe eczema (atopic dermatitis) that hasn't been helped enough by creams. The study is in early phases, so it will check how safe the drug is and how well it might work.
Irvine, CaliforniaAges 18–72 - NCT05099315Recruiting
Gut microbiome study in adults with severe eczema
This trial studies the gut microbiome in people with moderate to severe atopic dermatitis (eczema) who are starting or already receiving systemic (whole-body) treatment. It may help researchers understand what changes in gut bacteria are linked to eczema and to treatment response.
Berlin, State of BerlinAges 18 years+ - NCT07259343Recruiting
Cream with milk peptide for children's mild eczema
This trial tests if a special cream made with a milk protein peptide can improve mild eczema symptoms like itching and reduce bacteria on the skin in children aged 2 to 12.
Aguascalientes, AguascalientesAges 2–12 - NCT07560618RecruitingPhase 4
Testing a new cream for itch relief in atopic dermatitis
This study tests whether roflumilast cream (a new anti-inflammatory medication applied to the skin) can reduce the intense itching caused by atopic dermatitis (eczema). You'll track your itching daily using a smartphone app and visit the clinic to see if the cream helps over time.
Sacramento, CaliforniaAges 12 years+ - NCT06238765Recruiting
Adolescent Eczema Drug Safety Registry
This registry tracks the safety and effectiveness of medications used for moderate to severe atopic dermatitis (eczema) in adolescents aged 10 to 15. It helps doctors understand how well these treatments work and what side effects might occur over time.
Waltham, MassachusettsAges 10–15 - NCT06547372Recruiting
Dietary changes for eczema relief
This study tests whether a specific diet can help manage mild to moderate eczema. It involves eating whole foods provided by the researchers for a set period and tracking your skin health.
Singapore, SingaporeAges 21–65 - NCT07216027RecruitingPhase 2
A study of a new eczema medicine for adults
This trial tests a study drug (PF-08049820) for people with moderate to severe eczema who haven't found a suitable prescription treatment. It aims to see if the drug can improve skin symptoms and itching.
Phoenix, ArizonaAges 18–64 - NCT07183423Recruiting
New skin barrier product vs. Vaseline for dry, irritated skin
This study tests a new skin barrier product against a standard moisturizer (petrolatum) to see which works better for mild to moderate skin problems like eczema, psoriasis, or dry skin. It may help improve your skin's barrier and reduce symptoms.
Makati City, National Capital RegionAges 18 years+ - NCT07404033RecruitingPhase 1
Testing a lotion for mild to moderate dandruff rash
This trial tests a new lotion for people with mild to moderate seborrheic dermatitis (a common skin condition causing red, scaly patches on the scalp, face, or chest). The study checks safety and how well the lotion works.
Suzhou, JiangsuAges 18–65 - NCT07386743RecruitingPhase 3
New injection for moderate-to-severe eczema
This study tests a new injection called GS101 compared to an existing treatment (Dupixent) for people with moderate-to-severe atopic dermatitis (eczema). If you join, you may receive either the new drug or the standard treatment, and researchers will track how well it controls your symptoms.
Shenyang, LiaoningAges 18–75 - NCT07455578RecruitingPhase 1
Study of S-4321 for people with autoimmune or immune diseases
This trial tests a new medicine, S-4321, for people with various autoimmune conditions like rheumatoid arthritis, psoriasis, eczema, or lupus. It aims to see if the drug is safe and can help control the overactive immune system.
Charlestown, New South WalesAges 18–75 - NCT07453602RecruitingPhase 1
Study of ARQ-234 for healthy adults and those with atopic dermatitis
This trial tests a new medication called ARQ-234 in healthy adults and people with moderate-to-severe atopic dermatitis (eczema). The study looks at how the body handles single and multiple doses, and if it can help treat eczema.
Miami, FloridaAges 18–65 - NCT07021495Recruiting
Skin disease study to improve treatment choices
This study looks at different skin diseases to find markers that can help guide treatment. It tests new treatments for several conditions like eczema, psoriasis, and lupus, with the goal of personalizing care.
Nijmegen, GelderlandAges 18 years+ - NCT06182436Recruiting
Virtual reality for pain during eczema injection
This trial tests whether playing a virtual reality game during a dupilumab injection (for eczema) can help reduce pain and anxiety. It's for kids and teens aged 6 to 17 who are already taking or about to start this medicine.
Montreal, QuebecAges 6–17 - NCT06599411Recruiting
Skin biomarkers for inflammatory disease treatment
This study looks for clues in your skin and blood that could predict how well you'll respond to treatments for conditions like eczema, psoriasis, or lupus. It aims to help doctors choose the best therapy for you.
ParisAges 18 years+ - NCT06564389RecruitingPhase 1
First-in-human study of PF-07832837 in healthy adults and eczema patients
This trial is testing a new investigational medicine (PF-07832837) for safety in healthy adults and in people with moderate to severe atopic dermatitis (eczema). It is a first-in-human study, so it looks at how well the body tolerates the medicine.
Anaheim, CaliforniaAges 18–70 - NCT05268107RecruitingPhase 4
Study dupilumab skin effects in different ethnic groups
This Phase 4 study looks at how dupilumab works in people with moderate-to-severe atopic dermatitis (eczema), and whether the mechanism differs across ethnic backgrounds. If you’re eligible, it may help doctors understand who benefits most from dupilumab.
Ann Arbor, MichiganAges 18 years+ - NCT05721937Recruiting
Safety study of CIBINQO in pregnancy and baby outcomes
This study tracks the safety of abrocitinib (CIBINQO) during pregnancy and what it may mean for the baby. You may join if you were pregnant recently or are currently pregnant and have taken CIBINQO, or if you have moderate-to-severe atopic dermatitis.
New York, New YorkAges birth+ - NCT05026554Recruiting
Study of long-term eczema on hands
This trial studies chronic hand eczema (and sometimes related atopic skin disease) to better understand your condition and what may be going on in the skin. You may be asked to follow a study plan for a set period and avoid certain treatments just before joining.
Montreal, QuebecAges 18–65 - NCT00605878Recruiting
Skin microbiome study in healthy people and eczema patients
This study looks at the types of germs on the skin (skin microbiome) in healthy people and people with skin conditions, including atopic dermatitis (eczema). Researchers collect skin samples to understand how skin germs differ and how that may relate to skin health.
Bethesda, MarylandAges 2–100 - NCT07207954RecruitingPhase 1
Testing LFD-200 in healthy adults and adults with rheumatoid arthritis
This study tests a new drug, LFD-200, in healthy adults and in adults with moderate to severe rheumatoid arthritis who have active symptoms despite methotrexate. The goal is to see if it's safe and how it affects the disease.
MelbourneAges 18–75 - NCT07131410Enrolling by invitation
Hyaluronic acid cream to prevent foot ulcers in diabetes
This trial tests a cream made with hyaluronic acid, a natural substance that helps keep skin moist, to see if it can prevent foot sores in people with type 2 diabetes and nerve damage in their feet. If you have diabetes-related nerve issues and want to protect your feet, this study may be for you.
MálagaAges 18 years+ - NCT06593392RecruitingPhase 2
Safety of difelikefalin for itching in teens on dialysis
This trial tests a drug called difelikefalin to see if it safely reduces moderate-to-severe itching in teenagers who are on hemodialysis. Itching is common in kidney disease, and this study aims to find a new treatment option.
ChengduAges 12–18
Hear when a new Moderate to Severe Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for moderate to severe atopic dermatitis?
- Yes. Clin2 currently lists 95 recruiting moderate to severe atopic dermatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a moderate to severe atopic dermatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a moderate to severe atopic dermatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.